Sponsored message
Logged in as
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen

This archival content was originally written for and published on KPCC.org. Keep in mind that links and images may no longer work — and references may be outdated.

KPCC Archive

Too many are getting unnecessary prostate treatment, UCLA study says

A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.
The new test, which goes on sale Wednesday, joins another one that recently came on the market.
(Photo: Dr. Katsuto Shinohara (R) and Dr. Surat Dhonsombat look at a video monitor as they perform a bracytherapy operation on a man with prostate cancer at the UCSF Comprehensive Cancer Center in San Francisco)
A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. The new test, which goes on sale Wednesday, joins another one that recently came on the market. (Photo: Dr. Katsuto Shinohara (R) and Dr. Surat Dhonsombat look at a video monitor as they perform a bracytherapy operation on a man with prostate cancer at the UCSF Comprehensive Cancer Center in San Francisco)
(
Justin Sullivan/Getty Images
)

One year ago, Congress defunded public media. Now that we're 100% community funded, please become a sustaining member or increase your existing membership today.

Listen 0:44
Too many are getting unnecessary prostate treatment, UCLA study says

A UCLA study of U.S. men over 66 with slow-growing prostate cancer found that nearly half of those who are not expected to live long enough to benefit from surgery or radiation are nevertheless getting it, despite national guidelines to the contrary.

Because prostate cancer typically grows slowly, some men may never need treatment for it. That’s especially true for those with a life expectancy of less than ten years, due to other illness or advanced age.

According to the National Cancer Institute, those types of cases call for "watchful waiting" or "active surveillance," which mean close monitoring of a patient's condition without providing any treatment until symptoms appear or change, or if there is a change in test results. 

But the UCLA study found that many doctors are still opting for aggressive measures in these cases.

After reviewing the cases of 96,000 men with early-stage prostate cancer, UCLA's researchers found that more than half had life expectancies of less than ten years, and of those, half were receiving surgery, radiation or brachytherapy, the implantation of radioactive seeds in the prostate.

These treatments carry with them a high risk of erectile dysfunction, urinary incontinence and bowel problems.

Researchers say the study underscores the need for integrating life expectancy into prostate cancer treatment decisions.

The findings are published in the Dec. 1 edition of the journal “Cancer.”

Sponsored message
One year ago, Congress voted to defund public media, eliminating a critical $1.7 million from our budget every year going forward. But they couldn’t silence us, and we’re not going anywhere. LAist is now 100% community funded and that means we’re taking our future into our own hands and turning to you to keep local reporting strong.

You come to LAist because you want independent reporting and trustworthy local information. Our nonprofit newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our communities. We are free to follow facts wherever they lead and to hold power to account without fear or favor. Our only loyalty is to our readers and listeners and our mission: to inform, engage, and strengthen Southern California’s communities.

If this story helped you, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Senior Vice President News, Editor in Chief

Make your tax-deductible donation today